HFB101110 

HFB101110 is a human-derived inhibitor and Treg depleter that specifically targets CCR8. It does not bind to the homologous CCR4 receptor and is mainly used in research on solid tumors, renal cell carcinoma and colorectal cancer. HFB101110 blocks hCCL1 binding by interacting with the N-terminal extracellular domain of hCCR8, thereby inhibiting hCCL1-induced calcium influx, chemotaxis and downstream signaling pathways. Meanwhile, HFB101110 can mediate ADCC effects to specifically deplete CCR8-positive cells, including intratumoral Tregs. HFB101110 exhibits favorable anti-tumor activity and pharmacokinetic properties^[1][2].

Human

HFB101110 (0.01-10 nM) dose-dependently inhibits hCCL1-induced chemotaxis of CCR8⁺ cells^[1].
HFB101110 (10 μg/mL) completely inhibits hCCL1-induced calcium flux in CCR8⁺ cells^[1].
HFB101110 (0.3-300 μg/mL) does not induce significant cytokine release from healthy human PBMCs at concentrations up to 300 μg/mL^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

HFB101110 exerts potent single-agent antitumor activity in a human CCR8 knock-in mouse model via depletion of intratumoral regulatory T cells^[2].
HFB101110 is well-tolerated in wild-type mice^[2].
HFB101110 is well-tolerated in cynomolgus monkeys^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1237  [NCBI]

P51685

CCR8

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. PRIGENT J, et al. Anti-ccr8 antibodies and uses thereof: U.S. Patent Application 18/685,068[P]. 2025-1-16.

  [2]. Kumar R M, et al. Targeting regulatory T cells with HFB101110, a novel anti-human CCR8 antibody for the treatment of solid tumors[J]. Cancer Research, 2022, 82(12_Supplement): 2899-2899.